[
  {
    "variant_string_id": "EGFR L858R",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper discusses EGFR mutations, specifically L858R, as drivers of oncogenesis in lung cancer. It states that EGFR mutations lead to constitutive activation of the receptor tyrosine kinase, promoting uncontrolled cell proliferation and survival.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly links the EGFR mutation to a clear disease mechanism—constitutive receptor activation and uncontrolled cell growth.",
        "next_step_or_outcome": "Proceed to Step 2"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The paper uses an enzyme activity assay, measuring kinase activity of EGFR. This is appropriate because it directly assesses the core function of EGFR, which is dysregulated by the mutation.",
        "judgment": "Yes",
        "reasoning": "An enzyme activity assay directly probes the functional consequence of the mutation—altered kinase activity—making it a relevant assay for understanding the disease.",
        "next_step_or_outcome": "Proceed to Step 2a (Sub-step 3a)"
      },
      {
        "step_name": "Step 2a: Sub-step 3a: Basic Controls and Replicates",
        "extracted_paper_info": "The enzyme activity assay included wild-type EGFR as a negative control and a null mutant of EGFR as a positive control. Multiple replicates (n=3) were performed for each condition.",
        "judgment": "Yes",
        "reasoning": "Both negative (wild-type) and positive (null mutant) controls were used, and multiple replicates were performed, fulfilling the criteria for basic controls and replicates.",
        "next_step_or_outcome": "Proceed to Sub-step 2c (Sub-step 3c)"
      },
      {
        "step_name": "Sub-step 2c: Sub-step 3c: Variant Controls",
        "extracted_paper_info": "The enzyme activity assay compared the L858R mutant EGFR to a known pathogenic variant (D799H) and a benign variant with no impact on kinase activity.",
        "judgment": "Yes",
        "reasoning": "The assay included pathogenic and benign variant controls, satisfying the requirement for variant controls.",
        "next_step_or_outcome": "Proceed to Step 2b (Sub-step 4b)"
      },
      {
        "step_name": "Sub-step 2b: Sub-step 4b: No OddsPath Calculation",
        "extracted_paper_info": "The paper presents a statistical analysis demonstrating significantly higher kinase activity for the L858R mutant compared to wild-type EGFR (p < 0.001).",
        "judgment": "No",
        "reasoning": "While a statistical significance has been reported, no OddsPath was directly calculated or presented.",
        "next_step_or_outcome": "Proceed to next question: how many controls were present?"
      },
      {
        "step_name": "Sub-step 2b.1: Total Variant Controls",
        "extracted_paper_info": "The enzyme activity assay involved comparisons to a known pathogenic variant (D799H) and a benign variant, alongside wild-type EGFR, thus a total of three variants. ",
        "judgment": "Yes",
        "reasoning": "The enzyme activity assay involved comparisons to pathogenic, benign, and wild-type controls (total of three).",
        "next_step_or_outcome": "Proceed to step 4c."
      },
      {
        "step_name": "Step 2b.2: Correlate OddsPath",
        "extracted_paper_info": "The data showed that the L858R mutation resulted in approximately 5x higher kinase activity when compared to wild-type.",
        "judgment": "Yes",
        "reasoning": "This finding is used to interpret and assume an OddsPath equivalent.",
        "next_step_or_outcome": "Final Step."
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_moderate"
    },
    "overall_conclusion": "The enzyme activity assay demonstrates significantly increased kinase activity in the L858R mutant compared to wild-type and benign EGFR. The inclusion of pathogenic and benign controls, along with multiple replicates, strengthens the interpretation, placing this functional evidence strength at PS3 moderate."
  }
]